MongoDB Form 144 Discloses Insider Sales and 10b5-1 Reference
Rhea-AI Filing Summary
MongoDB, Inc. (MDB) Form 144 reports a proposed sale of 3,332 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $1,051,612.52, scheduled approximately for 09/02/2025. The filing states these 3,332 shares were acquired on 10/01/2009 as a VC investment from the issuer and paid in cash. The notice also discloses related sales in the past three months: 6,668 shares sold for $2,000,400 by Charles M Hazard Jr. and 1,336 shares sold for $400,800 by The Narragansett Bay Children’s Trust, both on 08/28/2025. The filing references Rule 10b5-1 but does not provide a plan adoption date in the form.
Positive
- Full transaction disclosure including broker, share count, aggregate market value and acquisition history is provided
- Past three-month sales by related parties are reported, aiding transparency and Rule 144 aggregation
Negative
- No plan adoption date is provided on the form despite referencing Rule 10b5-1, which is a relevant compliance detail
Insights
TL;DR: Filing discloses a routine Rule 144 sale and recent 10b5-1-related dispositions; documentation appears to meet Rule 144 disclosure elements.
The Form 144 lists the broker, number of shares, aggregate market value and acquisition details required under the rule. It also reports related dispositions within the last three months, which helps aggregate required sales for compliance. The form references a 10b5-1 plan but omits the plan adoption date, which is an important compliance detail if relying on that defense; the filer represents no undisclosed material adverse information.
TL;DR: Insider-related selling activity is disclosed but represents a small fraction of outstanding shares; impact on float appears limited.
The proposed sale of 3,332 shares (market value ~$1.05M) and recent sales totaling 8,004 shares (~$2.4M gross proceeds) are quantitatively small relative to the reported 81,356,893 shares outstanding. From a market-impact perspective, these transactions are unlikely to materially affect share supply or valuation given the company’s outstanding share base.